Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Strayer
R Henry

Showing results (741-750 of 1,415) with videos related to

Pageof 142
Sort By:
Acta Cytologica|August 2, 2001
Cervical cancer screening, screening errors and reportingV Schneider, M R Henry, M Jimenez-Ayala, et al.
Diabetes, Obesity & Metabolism|January 6, 2011
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetesA Garber, R R Henry, R Ratner, et al.
Endocrinology|June 16, 2007
Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cellsTheodore P Ciaraldi, Svetlana E Nikoulina, Rahil A Bandukwala, et al.
Bulletin Du Cancer|October 1, 1976
[Study of the influence of tobacco usage on circulating CEA levels]B Meriadec de Byans, P Ducimetierre, J L Salard, et al.
Science (New York, N.Y.)|May 8, 2004
Fluctuations and bistabilities on catalyst nanoparticlesV Johánek, M Laurin, A W Grant, et al.
JAAPA : Official Journal of the American Academy of Physician Assistants|March 16, 2007
Cardiometabolic risk modification: current trends and emerging therapiesJoseph L Lillo, George Bray, Stephen C Woods, et al.
Lancet (London, England)|June 12, 2009
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging studyRobert R Henry, A Michael Lincoff, Sunder Mudaliar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 24, 2026
Mesocorticolimbic connectivity and motivational sensitivity: sex-specific effects of puberty in early adolescenceAmar Ojha, Teague R Henry, Neil P Jones, et al.
Journal of Diabetes and Its Complications|March 18, 2014
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetesRobert R Henry, Julio Rosenstock, Douglas Logan, et al.
Journal of Animal Science|January 7, 1998
Relative bioavailability of supplemental inorganic zinc sources for chicksM Sandoval, P R Henry, C B Ammerman, et al.
Pageof 142

Showing results (741-750 of 1,415) with videos related to

Sort By:
Pageof 142
Acta Cytologica|August 2, 2001
Cervical cancer screening, screening errors and reportingV Schneider, M R Henry, M Jimenez-Ayala, et al.
Diabetes, Obesity & Metabolism|January 6, 2011
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetesA Garber, R R Henry, R Ratner, et al.
Endocrinology|June 16, 2007
Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cellsTheodore P Ciaraldi, Svetlana E Nikoulina, Rahil A Bandukwala, et al.
Bulletin Du Cancer|October 1, 1976
[Study of the influence of tobacco usage on circulating CEA levels]B Meriadec de Byans, P Ducimetierre, J L Salard, et al.
Science (New York, N.Y.)|May 8, 2004
Fluctuations and bistabilities on catalyst nanoparticlesV Johánek, M Laurin, A W Grant, et al.
JAAPA : Official Journal of the American Academy of Physician Assistants|March 16, 2007
Cardiometabolic risk modification: current trends and emerging therapiesJoseph L Lillo, George Bray, Stephen C Woods, et al.
Lancet (London, England)|June 12, 2009
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging studyRobert R Henry, A Michael Lincoff, Sunder Mudaliar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 24, 2026
Mesocorticolimbic connectivity and motivational sensitivity: sex-specific effects of puberty in early adolescenceAmar Ojha, Teague R Henry, Neil P Jones, et al.
Journal of Diabetes and Its Complications|March 18, 2014
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetesRobert R Henry, Julio Rosenstock, Douglas Logan, et al.
Journal of Animal Science|January 7, 1998
Relative bioavailability of supplemental inorganic zinc sources for chicksM Sandoval, P R Henry, C B Ammerman, et al.
Pageof 142